New Approach Methodologies for Drug Discovery and Development

Innovative tools driving more predictive, human-relevant science

Drug discovery and development are undergoing a paradigm shift, demanding a move beyond traditional animal models. Integrating advanced technologies like in vitro models, in silico tools, and VCGs is no longer optional—it’s essential to improve nonclinical evaluations, enhance translational accuracy, and stay ahead in delivering innovative therapies.

For early de-risking and improved translation, human complex in vitro models deliver unparalleled value to our clients. These sophisticated systems replicate human biology with precision, offering critical insights into drug efficacy and safety. By integrating these models into your research, you can identify risks earlier, improve decision-making, and partially replace animal models, saving time and resources. 

WEBINAR: Maximize Safer, Targeted Biologic Development with Smarter NAMs-Based Off-Target Screening
This webinar showcases how the Retrogenix^® platform empowers smarter, earlier decisions across biologic formats. You’ll also learn how this platform, recently accepted into the FDA’s ISTAND Pilot Program, aligns with evolving regulatory support for NAMs and the shift toward reduced animal use.
Watch the Replay

Predictive toxicology in silico models further elevate preclinical research. With AI-driven simulations, you can anticipate toxicological risks well before clinical trials, reducing late-stage failures and associated costs. These tools provide a comprehensive and reliable framework for de-risking drug candidates while expediting regulatory approvals.

"We are dedicated to advancing the 3Rs and ensuring safe, effective alternatives that accelerate your drug discovery and development journey, with your success and goals at the heart of everything we do."
Shannon Parisotto, Corporate Executive Vice President, Global Discovery and Safety Assessment

Virtual Control Groups (VCGs) are transforming safety assessment studies through innovative alternatives that reduce dependence on animal models while preserving scientific integrity. By using historical data, advanced analytics, and machine learning, VCGs simulate control groups virtually, enabling faster, more cost-effective studies without compromising accuracy. This breakthrough approach aligns with ethical standards allows you to accelerate your research and development pipelines.

Together, in vitro models and in silico tools provide advanced solutions to streamline drug development, enabling faster, safer, and more ethical delivery of innovative therapies to patients because every moment matters.

Talk to an Expert

LSX World Congress
Charles River joins LSX USA 2025 to present on New Approach Methodologies (NAMs)—advancing innovation, investment, and partnerships in the future of healthcare.
View the event